Skip to main content
SpringerLink
Log in

The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The contribution of the enzymes CYP2D6 and CYP2C19 to the metabolism of artemether was evaluated in a cross-over study in seven healthy adult Caucasian subjects. The pharmacokinetic properties of artemether and its active metabolite dihydroartemisinin were compared when given 100 mg artemether orally alone or in combination with either CYP2D6-inhibitor quinidine or CYP2C19-inhibitor omeprazole. Plasma concentrations of artemether and dihydroartemisinin were measured with reversed phase high performance liquid chromatography with electro-chemical detection (HPLC-ED). Artemether was rapidly absorbed with a mean tmax of 0.8 h (95% confidence interval, CI=0.5–1.1) reaching a mean Cmax of 29 ng/ml (14–45 ng/ml). The mean elimination half-life was 1.3 h (0.8–1.8 h). The pharmacokinetic parameters for dihydroartemisinin were not significantly different from those for artemether. Artemether combined with quinidine revealed no significant changes in the plasma concentrations of either artemether or dihydroartemisinin. No changes were seen in the combination with omeprazole as a CYP2C19 inhibitor. A second peak in the plasma concentration profile was observed 2–4 h after drug intake. This phenomenon was possibly related to variable gastric emptying. No major contribution of the enzymes CYP2D6 or CYP2C19 was found in artemether metabolism. No interethnic differences in artemether metabolism on the basis of a genetic polymorphism of these enzymes is to be expected.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wernsdorfer W. (1991): The development and spread of drug resistant malaria. Parasitol Today; 7; 297–303.

    Article  CAS  PubMed  Google Scholar 

  2. Hien T.T., White N.J. (1993): Qinghaosu. Lancet, 341, 603–608.

    Article  CAS  PubMed  Google Scholar 

  3. Klayman D. (1985): Qinghaosu (artemisinin): an antimalarial drug from China. Science, 228, 1049–1055.

    Article  CAS  PubMed  Google Scholar 

  4. De Vries P.J., Tran K.D. (1996): Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs, 52, 818–836.

    Article  PubMed  Google Scholar 

  5. Van Boxtel C.J., de Vries P.J., Tran K.D., Koopmans R.P., Kager P.A. (1995): Pharmacokinetics of artemisinin and derivatives. Proceedings of the 7th Southeast Asian/Western Pacific Regional Meeting of Pharmacologists. Manila, Philippines:Towards Rational Drug Therapy at the Turn of the Century, 498–504.

    Google Scholar 

  6. Van Boxtel C.J., van Agtmael M.A., de Vries P.J., Tran K.D., Koopmans R.P., Kager P.A. (1996): Some pharmacokinetic and dynamic comparisons of artemisinin derivatives in man. Jpn. J. Trop. Med. Hyg., 24, 4954.

    Google Scholar 

  7. Bangchang K., Karbwang J. (1994): Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute, uncomplicated falciparum malaria. Br. J. Clin. Pharmacol., 37, 249–253.

    CAS  Google Scholar 

  8. Mordi M.N., Mansor S.M., Navaratnam V., Wernsdorfer W.H. (1997): Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteers. Br. J. Clin. Pharmacol., 43, 363–365.

    Article  CAS  PubMed  Google Scholar 

  9. Lee I.S., Hufford C.D. (1990): Metabolism of antimalarial sesquiterpene lactones. Pharmacol. Ther., 48, 345–355.

    Article  CAS  PubMed  Google Scholar 

  10. Bertilsson L. (1995): Geographical/interracial differences in polymorphic drug oxidation, current state of knowledge of cytochromes P450 (CYP2D6 and 2C19). Clin. Pharmacokinet., 29, 192–209.

    Article  CAS  PubMed  Google Scholar 

  11. Tucker G.T. (1994): Clinical implications of genetic polymorphism in drug metabolism. J. Pharm. Pharmacol., 46, 417–424.

    CAS  PubMed  Google Scholar 

  12. Kevin Park B., Munir Pirmohamed, Kitteringham N.R. (1995): The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol. Ther., 68, 385–424.

    Article  Google Scholar 

  13. Brewer T.G., Peggins J.O., Grate S.J. et al., (1994): Neurotoxicity in animals due to arteether and artemether. Trans. R. Soc. Trop. Med. Hyg., 88 Suppl 1, 3336.

    Google Scholar 

  14. Zhou H.H., Anthony L.B., Roden D.M., Wood A.A.J. (1990): Quinidine reduces clearance of (+)-propranolol more than (−)-propranolol through marked reduction in 4-hydroxylation. Clin. Pharmacol. Ther.; 47, 686–693.

    Article  CAS  PubMed  Google Scholar 

  15. Speirs C.J., Murray S., Boobis A.R., Seddon C.E., Davies D.S. (1986): Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br. J. Clin. Pharmacol., 22, 739–743.

    CAS  PubMed  Google Scholar 

  16. Balian J.D., Sukhova N., Harris J.W. et al. (1995): The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin. Pharmacol. Ther., 57, 662–669.

    Article  CAS  PubMed  Google Scholar 

  17. Chang M., Tybring G., Dahl M.L. et al. (1995): Interphenotype differences in disposition on gastrin levels of omeprazole. Suitability of omeprazole as a probe for CYP2C19. Br. J. Clin. Pharmacol., 39, 511–518.

    CAS  PubMed  Google Scholar 

  18. Caraco Y., Tateishi T., Wood A.J. (1995): Interethnic difference in omeprazole’s inhibition of diazepam metabolism. Clin. Pharmacol. Ther., 58, 62–72.

    Article  CAS  PubMed  Google Scholar 

  19. Melendez V., Peggins J.O., Brewer T.G., Theoharides A.D. (1991): Determination of the antimalarial arteether and its de-ethylated metabolite dihydroartemisinin in plasma by highperformance liquid chromatography with reductive electrochemical detection. J. Pharm. Sci., 80:132–138.

    Article  CAS  PubMed  Google Scholar 

  20. Van Agtmael M.A., Butter J.J., Portier E.J.G., Van Boxtel C.J. (1998): Validation of an improved reversed phase high performance liquid chromatography assay with reductive electrochemical detection for the determination of artemisinin derivatives in man. Ther. Drug Monit., 20, 109–116.

    Article  PubMed  Google Scholar 

  21. Scientist for experimental data fitting (1986–1995). Salt Lake City. Utah: Micromath Scientific Software.

    Google Scholar 

  22. Altman D.G. (1991): Comparing groups-continuous data. In: Practical statistics for medical research, 1st edn. London: Chapman & Hall.

    Google Scholar 

  23. Machin D., Campbell M.J., Fayers P.M., Pinol A.P.Y. (1987, 1997): Sample size tables for clinical studies, 2nd edn. Berlin: Blackwell Science.

    Google Scholar 

  24. Teja-Isavadharm P., Nosten F., Kyle D.E. et al. (1996): Comparative bioavailability of oral, rectal and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. Br. J. Clin. Pharmacol., 42, 599–604.

    CAS  PubMed  Google Scholar 

  25. Van Agtmael M.A., Xiu-qing J., Koopmans R.P., Degen P., Royce C.M., Van Boxtel C.J. (1996): Multiple dose pharmacokinetics of artemether in Chinese patients treated for falciparum malaria. Abstracts of the VIth World Conference on Clinical Pharmacology and Therapeutics, Buenos Aires, Argentina, August 1996. Acta Physiologica Pharmacologica et Therapeutica Latinoamerica, p 244.

  26. Kokwaro G.O. (1997): Bioavailability of artemether. Br. J. Clin. Pharmacol., 44, 303–305.

    Google Scholar 

  27. Karbwang J., Nabangchang K., Congpuong K., Molunto P. Thanavibul A. (1997): Pharmacokinetics and bioavailability of oral and intramuscular artemether. Eur. J. Clin. Pharmacol., 52, 307–310.

    Article  CAS  PubMed  Google Scholar 

  28. Oberle R.L., Amidon G.L. (1987): The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J. Pharmacokinet. Biopharm., 15, 529–544.

    Article  CAS  PubMed  Google Scholar 

  29. Hammarlund M.M., Paalzow L.K., Odlind B. (1984): Pharmacokinetics of furosemide in man after intravenous and oral administration; application of moment analysis. Eur. J. Clin. Pharmacol., 26, 197–207.

    Article  CAS  PubMed  Google Scholar 

  30. Clements J.A., Heading R.C., Nimmo W.S., Prescott L.F. (1978): Kinetics of acetaminophen on absorption and gastric emptying in man. Clin. Pharmacol. Ther., 24, 420–431.

    CAS  PubMed  Google Scholar 

  31. Lui C.Y., Oberle R., Fleisher D., Amidon G.L. (1986): A radiotelemetric method for evaluation of enteric coating performance: comparison of enteric-coated and plain aspirin tablets. J. Pharm. Sci., 75, 469–474.

    Article  CAS  PubMed  Google Scholar 

  32. Macheras P., Argyrakis P. (1997): Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity? Pharm. Res., 14, 842–847.

    Article  CAS  PubMed  Google Scholar 

  33. Ngo Thu Hoa, Michoel A., Kinget R. (1996): Dissolution testing of artemisinin solid oral dosage forms. Int. J. Pharm., 138, 185–190.

    Article  Google Scholar 

  34. Svensson U.S.H., Ashton M., Hai T.N. et al. (1996): Artemisinin and omeprazole pharmacokinetics in healthy male subjects after repeated co-administration; omeprazole as in vivo marker for CYP3A4 and 2C19. Abstracts of the XIVth International Congress for Tropical Medicine and Malaria, Nagasaki, Japan, November 1996. Abstr. P-01-76, p 341.

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology and Pharmacotherapy, Academic Medical Centre, Meibergdreef 9, 1105, Amsterdam, The Netherlands

    M. A. Van Agtmael, C. A. A. Van Der Graaf, T. K. Dien, R. P. Koopmans & C. J. Van Boxtel

  2. Institute for Clinical Research in Tropical Medicine, Bach Mai Hospital, Hanoi, Vietnam

    T. K. Dien

Authors
  1. M. A. Van Agtmael
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. A. A. Van Der Graaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. K. Dien
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. P. Koopmans
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. J. Van Boxtel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Van Agtmael, M.A., Van Der Graaf, C.A.A., Dien, T.K. et al. The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur. J. Drug Metab. Pharmacokinet. 23, 429–436 (1998). https://doi.org/10.1007/BF03192305

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03192305

Keywords

Search

Navigation